

**DDX5 promotes gastric cancer cell proliferation in vitro and in vivo  
through mTOR signaling pathway**

Cheng Du<sup>1\*</sup>, Dan-qi Li<sup>2\*</sup>, Na Li<sup>3\*</sup>, Li Chen<sup>4\*</sup>, Shi-sen Li<sup>5</sup>, Yang Yang<sup>6</sup>,  
Ming-xiao Hou<sup>7</sup>, Man-jiang Xie<sup>4</sup> and Zhen-dong Zheng<sup>1</sup>

1 Department of Oncology, General Hospital of Shenyang Military Area  
Command, Shenyang 110840, P. R. China

2 Institute of Molecular Research, Shenyang University of Chemical  
Technology, Shenyang 110142, P. R. China

3 Department of Gynaecology and Obstetrics, First Affiliated Hospital,  
Jilin University, Jilin 130021, P. R. China

4 Department of Aerospace Medicine, Fourth Military Medical University,  
Xi'an 710032, P. R. China

5 Department of Digestive Surgery, Xijing Hospital of Digestive Diseases,  
The Fourth Military Medical University, Xi'an 710032, China.


6 Department of Oncology, Xijing Hospital, Fourth Military Medical  
University, Xi'an 710032, P. R. China

7 Rescue Center of Severe Wound and Trauma of PLA, General Hospital  
of Shenyang Military Area Command, Shenyang 110840, P. R. China.

\*These authors have contributed equally to this work

Correspondence and requests for materials should be addressed to: Z.D.Z.  
(mylonzzdong@163.com), M.J.X. (manjiangxie@hotmail.com) and

M.X.H. (houmingxiao188@163.com).



**Figure S1.** Relative quantification of the blots of DDX5, p-mTOR/mTOR and p-S6K1/S6K1 in (A) KATO III and (B) NCI-N87 cells treated as above indicated.

(\* $p < 0.05$ ; NS, no significance).